Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qutenza versus placebo in painful diabetic peripheral neuropathy
2025-523597-17-00Phase 2Authorised
- Sponsor
- German Diabetes Center
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing Qutenza with Placebo patch (2 arms). Primary endpoint: Change from baseline in IENFD (PGP9.5) at repeated-treatment site at Week 35. Planned start Jan 2026; status: authorised.
02
Drugs
capsaicin
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2025-523597-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523597-17-00.